

#3/a
pr
3.14.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Avi J. Ashkenazi Serial No.: To be assigned Filed: December 13, 1999 For: Apo-2 Ligand	Group Art Unit: To be assigned Examiner: To be assigned
---	--

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This Preliminary Amendment is being filed concurrently with Applicant's Rule 53(b) Continuation Application. Applicant respectfully requests entry of the following preliminary amendment prior to examination on the merits.

In the Specification:

Please delete pages 68-75 of the specification's originally filed Sequence Listing and enter into the specification the substitute Sequence Listing attached hereto (comprising page numbers 1-11).

On page 6, line 20, after "cDNA," insert -- (SEQ ID NO:2) -- and after "sequence," insert -- (SEQ ID NO:1) --.

On page 6, line 22, after "ligand," insert -- (Apo2L amino acids 114-281 of SEQ ID NO:1) --.

On page 6, line 23, after "4-1BBL," insert -- (SEQ ID NO:9) --.

On page 6, line 23, after "OX40L," insert -- (SEQ ID NO:10) --.

On page 6, line 23, after "CD27L," insert -- (SEQ ID NO:11) --.

On page 6, line 23, after "CD30L," insert -- (SEQ ID NO:12) --.

On page 6, line 23-24, after "TNF-alpha," insert -- (SEQ ID NO:13) --.